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more, regulatory requirements stipulate that a new orphan status application
must be submitted for each indication. Under EMA regulations, orphan and non-
orphan indications cannot be granted under the same marketing authorization.
Although expansions between orphan and non-orphan indications are more com-
mon in the US, no examples of expansion from a non-orphan to orphan indication
were identified by the authors. CONCLUSIONS: While indication expansion be-
tween orphan indications is relatively common, examples of expansion into or out
of orphan indications are less frequent due to the regulatory restrictions. Pricing
and reimbursement dynamics in all cases are reflective of the trade-offs between
price potential and population size across indications.
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OBJECTIVES: Korea introduced a new positive list system in 2007 together with a
price negotiation procedure. Importantly, these two systems are run by two differ-
ent, independent organizations, namely the Health Insurance Review & Assess-
ment Service (HIRA) and the National Health Insurance Corporation (NHIC). HIRA
reviews the cost-effectiveness data in submissions and makes listing decisions,
then NHIC takes over and sets the reimbursement price via negotiations with
manufacturers. The aim of this study is to compare the difference in price after
cost-effectiveness appraisal by HIRA and price negotiation by NHIC, and to analyze
the factors that NHIC has considered to determine the reimbursement price.
METHODS: All 35 submissions made to the NHIC between August 2007 and June
2008 were reviewed. 19 submissions concluded with agreement, 15 failed and one
case was suspended. In this review only 15 cases of successful negotiations were
included. The level of the reimbursement price compared to the submitted price for
both essential drugs and non-essential ones and factors affecting the final price
were analyzed.RESULTS:The discrepancy between reimbursement price and cost-
effective price was about 12.3311.44% on average. For 3 essential drugs, the price
level was almost equal to the submitted price whereas the average level was 84.94
11.21% of the cost-effective price for non-essential drugs. The major factors af-
fecting negotiations to determine the final price were narrowed down to total cost
of substitutes, the foreign price, and the pharmaceutical budget impact.
CONCLUSIONS: Our findings have demonstrated that drug pricing within the new
environment has been done independently of cost-effectiveness appraisal. The
payer has exhibited limited bargaining power for essential drugs. Overall, 87.67% of
the cost-effective price was accepted during price negotiations, and the total cost of
substitutes, foreign prices and pharmaceutical budget impact were considered
equally when fixing the reimbursement price. A limitation of this study is that the
result may not be generalized because of insufficient cases.
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OBJECTIVES: Primary research is often only conducted in a limited number of key
markets despite a product being launched across a wider range of countries. In
order to understand the implications of research findings across geographies, mar-
kets can be grouped by common underlying factors. METHODS: Market segmenta-
tion frameworks were developed based on key decision drivers which can be ap-
plied at different points in a product lifecycle. Within each framework, markets can
be segmented in up to two domains to distinguish segments. In-depth secondary
research was conducted in EU27 markets to understand key pricing, reimburse-
ment, access and uptake processes. Qualitative analysis of these findings permit-
ted us to place markets in the segmentation framework, allowing extrapolation of
findings across similar markets. RESULTS: Markets can be segmented in several
domains, depending on areas of interest for the research in question. For example,
in the case of peri-launch segmentation, most new pharmaceuticals aim to secure
optimal pricing and reimbursement – therefore an understanding of similarities
and differences in these areas are of greatest interest. Markets can be assessed in
terms of HTA data requirement, degree of centralization of decision making, pric-
ing regulations (fixed vs. ‘free’ pricing) or pricing decision drivers. This approach
was applied to understanding market similarities for a novel, hospital adminis-
tered product in a rare disease area. All 27 EU markets were segmented by level of
price regulation into three groups: price set by manufacturer, price set through
negotiation or strict price regulation. Understanding pricing drivers in each group
allowed results from primary research undertaken in only 6 of these markets to be
used by the manufacturer in all EU27 markets. CONCLUSIONS: Applying these
conceptual frameworks to drive market segmentation, key similarities and differ-
ences between markets can be used to extrapolate findings from primary market
research, or determine what strategic options are applicable to a given market.
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OBJECTIVES: In 1994, in French health care system, a supplement status for am-
bulatory reimbursement drugs, called “exception drugs”, was established. This
status enables to reimburse only specified indications of particularly costly drugs.
In this study we analyze what characteristics a drug should possess in order to be
considered as an exception drug. METHODS: Included in the study, were drugs
that had status of “exception drugs” as of April 2011. The clinical (actual benefit,
improvement of actual benefit) and economic (amount reimbursed by National
Health Insurance) characteristics were collected from official and publicly available
websources, as well as supplement restrictions for prescription (any prescription
or only the first one must be accomplished by a hospital practitioner; prescription
must be accomplished by a specialist; or prescription requires specific following
during the treatment). RESULTS: As of April 2011, there were 56 “exception drugs”
in trade name and 30 in generic name. The drugs from 9 ATC classes level I were
presented; the most numerous were A16 (Other alimentary tract and metabolism),
H01 (Pituitary and hypothalamic hormones and analogues), B03 (Antianemic prep-
arations). Supplement restrictions for prescription was applied to 33 drugs. Some
“exception drugs” (10) had also the status of drugs financed out of DRG payment
system. Most of the drugs, 91.07% (51/56) had high level of actual benefit. Around
half of the “exception drugs”, 42.86% (24/56) had level of improvement in actual
benefit from I to III. In 2009, part of reimbursed amount of “exception drugs” was
7.73% from all reimbursed drugs, whereas in 2004 it was 2.85%. Interestingly, in
2009 four exception drugs constituted about 1% of the reimbursed amount each,
and 40 – less than 0.1%. CONCLUSIONS: The analyzed types of characteristics, both
economic and clinical, can be used as criteria for establishing the status of excep-
tion drug.
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OBJECTIVES: Generic competition is an effective cost-containment mechanism
that improves static efficiency and stimulates pharmaceutical innovation. No prior
study has empirically analysed the relative delays in adoption of generic competi-
tion within the OECD. This study aims to investigate how price regulations in the
OECD affect timing of generic adoption following the first global generic launch.
METHODS: Drawing upon data from 1999 to 2008, we estimate the impact of ex-
ante price and market size expectations on the probability of generic launch using
discrete-time duration modeling with cloglog and logit regressions. The economet-
ric strategy employs both parametric and non-parametric duration dependence
and includes controls for local generic competition, firm characteristics and mol-
ecule heterogeneity. RESULTS: Ex-ante profit expectations result in faster adop-
tion; both expected price and market size increase the probability of launch. Our
findings suggest that neither molecule nor firm characteristics have a significant
effect on generic adoption across different specifications.CONCLUSIONS: Evidence
indicates that regulation has a significant impact on timing of adoption; however,
generic competitors tend to follow a locally oriented strategy in contrast to re-
search-intensive pharmaceutical firms.
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OBJECTIVES: Biosimilars are predicted to reduce prices of biologicals. Among bio-
similars, epoetin alfa has the largest market penetration in Germany and Spain.
The aim of this study was to describe the political, technological, economical and
social factors that impact on epoetin alfa sales and price in both European coun-
tries, which greatly differ in their generic market size. METHODS: Revisions of
regulatory legislation and policies regarding biosimilars at country and European
levels have been conducted. Estimations of market shares in units for epoetin alfa
originator and biosimilars plus darbopoetin alfa, a second generation biological,
were calculated. Epoetin alfa pricing trend was followed. All data was extracted
from IMS MIDAS database, using standard units and ex-manufacturer price.
RESULTS: Both countries are under the same regulatory framework and have pol-
icies that promote generic penetration, although automatic biosimilar substitution
is banned. Price of first launched biosimilar was approximately 30% below origina-
tor price in both countries. In Germany, originator price decreased about 16% after
launch of second biosimilar, whereas in Spain, originator price trend have no
changes to date. Regarding originator market shares, they did not change after
launch of biosimilars in Spain, while in Germany marked reductions were observed
along with biosimilars market share increases. In Spain, market shares of darbo-
poetin alfa were reduced when epoetin alfa biosimilar sales started, but no changes
of the kind were documented in Germany. CONCLUSIONS: Although both coun-
tries face similar political and technological factors; in Spain, social and economi-
cal ones could negatively impact stakeholder perception. In this country, the in-
troduction of biosimilars do not modify market share of the originator despite it
has a price about 30% higher. In Germany, stakeholders pose minimum resistance
to biosimilars, as market share and price of originator are immediately reduced
after the entry of biosimilars.
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OBJECTIVES:Most OECD countries employ pricing controls to contain rising health
care expenditures. The recent financial crisis has resulted in further pressure to
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